Is the type of diabetes treatment relevant to outcome of COVID-19?

Bloomgarden, Zachary

Bloomgarden, Zachary.

Bloomgarden Z; Department of Medicine, Division of Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York.

J Diabetes ; 12(7): 486-487, 2020 Jul.

Article in English | MEDLINE | ID: covidwho-611505

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Antiviral Agents/therapeutic use; Betacoronavirus/drug effects; Coronavirus Infections/drug therapy; Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents/therapeutic use; Pneumonia, Viral/drug therapy; Anti-Inflammatory Agents/adverse effects; Antiviral Agents/adverse effects; Betacoronavirus/pathogenicity; COVID-19; Coronavirus Infections/diagnosis; Coronavirus Infections/epidemiology; Coronavirus Infections/virology; Diabetes Mellitus, Type 2/diagnosis; Diabetes Mellitus, Type 2/epidemiology; Host-Pathogen Interactions; Humans; Hypoglycemic Agents/adverse effects; Pandemics; Pneumonia, Viral/diagnosis; Pneumonia, Viral/epidemiology; Pneumonia, Viral/virology; Risk Factors; SARS-CoV-2; Treatment Outcome; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Diabetes Mellitus, Type 2 / Betacoronavirus / Hypoglycemic Agents / Anti-Inflammatory Agents Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Diabetes Journal subject: Endocrinology Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google